A deep learning framework enhances medical image recognition by optimizing RNN architectures with LSTM, GRU, multimodal fusion, and CNN integration. It improves dynamic lesion detection, temporal ...

I put Gemini 3.0 and Grok 4.1 through 9 head-to-head prompts — from logic and creativity to humor and tone. Here's what ...

Interactive platforms like Codecademy and Dataquest.io let you learn and code right in your browser, making python online ...

Ongoing Phase 1b/2 Trial of the Allosteric MEK1/2 Inhibitor REC-4881 as Monotherapy (FAP): Updated Safety and Efficacy Najat Khan, Ph.D ., Chief R&D and Chief Commercial Officer and incoming CEO and ...

Najat Khan, PhD, unpacks realistic timelines for AI-based drugs to make clinical impact and her priorities for Recursion as incoming CEO.

Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, announced today that it will present ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is slated to report third-quarter 2025 results on Nov. 5, before the opening bell.

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Recursion Pharmaceuticals currently has the industry's largest AI supercomputer. It also has partnerships with major drugmakers, but these have yet to yield major wins. Recursion'a lack of clinical ...

SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Recursion Pharmaceuticals Inc. (RXRX) on Wednesday reported a loss of $162.3 million in its third quarter. The Salt Lake City-based company said it had a ...